InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
2
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-17.7%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by New Enterprise Associates 17, L.P.. Director active across 5 companies, notably Monte Rosa Therapeutics, Inc.. Cumulatively, 6 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €2.9m. History available since 22 April 2024. The latest transaction was disclosed on 10 March 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to New Enterprise Associates 17, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
207,100 股@ US$11.1167.8% 占其流量Common StockSEC:0001193125-26-104719:0
标准退出：2026年6月8日 (T+90)
1,619,240 股Common StockSEC:0001193125-26-046671:0
189,195 股@ US$0.01100.0% 占其流量Common StockSEC:0001193125-25-232131:0
1,023,103 股Common StockSEC:0000950170-24-107537:0
17,857 股@ US$56.00100.0% 占其流量Common StockSEC:0000950170-24-047686:0
标准退出：2024年7月21日 (T+90)
2,715,968 股Common StockSEC:0001209191-21-044033:0
6 条申报中的 6 条
About New Enterprise Associates 17, L.P.
New Enterprise Associates 17, L.P. is a declarant with 4 filings in total. In the 4 sampled recent filings, the only quantified transaction is a buy of EUR 938602, and the period covered runs from 2021-06-30 to 2024-09-17. The companies mentioned are Monte Rosa Therapeutics, Inc., MBX Biosciences, Inc. and Korro Bio, Inc.
